Launch follows MHLW approval of IMCIVREE for acquired hypothalamic obesity and inclusion on Japan's National Health Insurance ...

Disruption of the brain’s hunger and satiety control mechanisms can lead to rapid weight gain that is difficult to treat with conventional dietary interventions because patients do not experience an ...

Obesity associated with hypothalamic dysfunction was initially described in patients with craniopharyngioma. Hypothalamic obesity may also result from brain radiation, infection (eg, tuberculosis), ...

Rhythm Pharmaceuticals' (RYTM) early Imcivree feedback from four pediatric endocrinologists managing hypothalamic obesity patients is encouraging, RBC said in a note Thursday. RBC ...

Before GLP-1 agonists became the blockbuster obesity drugs many people know and use today, Rhythm Pharmaceuticals was researching molecules that take a similar approach but for a different target. The ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide plus concomitant GLP-1 therapy lowered BMI in children and adults with hypothalamic obesity.

A Prescription Drug User Fee Act target date of December 20, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) ...

Please provide your email address to receive an email when new articles are posted on . Setmelanotide was associated with sustained reductions in weight metrics in patients with acquired hypothalamic ...

The last time I spoke about Rhythm Pharmaceuticals, Inc. (RYTM) it was in a Seeking Alpha article entitled "Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder." With respect to ...

Bivamelagon showed significant BMI reductions in hypothalamic obesity patients, prompting Rhythm Pharmaceuticals to seek FDA guidance for Phase 3 trials. Rhythm Pharmaceuticals, Inc. announced ...

Rhythm Pharmaceuticals, Inc. ( RYTM) announced the commercial launch of Imcivree (setmelanotide) in Japan for acquired hypothalamic obesity, following its inclusion on the country's National Health ...

Rhythm Pharmaceuticals, Inc. announced the commercial launch of IMCIVREE® (setmelanotide) in Japan to treat patients living with acquired hypothalamic obesity (HO), following its inclusion on ...